Pharmacists in Milan, IL Accepting Medicare
8 Pharmacists found. Showing 1 - 8
 Cecilia Pham, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 440 10th Ave W, Milan, IL 61264 Phone: 309-787-2161 |
 Jerry L Smith, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 440 10th Ave W, Milan, IL 61264 Phone: 309-787-2161 Fax: 309-787-2673 |
Dr. Chelsey Marie Hogan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 440 10th Ave W, Milan, IL 61264 Phone: 309-787-2161 |
William Gutz, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 440 10th Ave W, Milan, IL 61264 Phone: 309-787-2161 Fax: 309-787-2673 |
Allen Koster, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 10th Ave W, Milan, IL 61264 Phone: 309-756-9907 |
Mudassar Ikram Buttar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 10th Ave W, Milan, IL 61264 Phone: 847-406-7816 |
Alan Phelps, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 10th Ave W, Milan, IL 61264 Phone: 309-756-9907 |
Janet Rafferty, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 10th Ave W, Milan, IL 61264 Phone: 309-756-9907 |
News Archive
Thymosin beta 4 improves neurological functional outcome
REGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.
Variations in microRNA expression within breast tumors can lead to sampling bias
Certain short strands of RNA, known as microRNAs (miRNAs), have been linked to the progression and metastasis of breast cancer and may provide information about prognosis. However, studies of miRNA expression profiles often report conflicting findings. While the potential for using miRNAs in breast cancer diagnosis is promising, scientists report in a new study published online today in The Journal of Molecular Diagnostics that differences in the amount and types of miRNA within breast tumors can be misleading.
Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
Study compares prevalence, impact of chronic pain amongst different ethnic groups in Tower Hamlets
A new study in the London Borough of Tower Hamlets, funded by medical research charity Arthritis Research UK, may help improve GPs' understanding of chronic musculoskeletal pain amongst different ethnic groups and develop better strategies for self-management as a result
› Verified 3 days ago